Good News about Lung Cancer? Thanks to Bench Science and Pharma

Good News about Lung Cancer? Thanks to Bench Science and Pharma By Kathleen Hoffman, PhD, MSPH Targeted therapies, monoclonal antibodies, and immune checkpoint inhibitors are the good news - making a significant difference in lung cancer mortality, a new study states. Published in The New England Journal of Medicine, the report said, “Mortality from NSCLC decreased even faster than the incidence ...and this decrease was associated with a substantial improvement in survival over time that corresponded to the timing of approval of targeted therapy.” 1Posts and reassurances that people read while visiting the American Lung Association’s Lung [...]